Unnatural Products, Inc. (UNP) received $32 million in Series A funding from a group of investors, including LongeVC, ARTIS Ventures, and the Merck Global Health Innovation Fund. The funds will advance UNP's AI platform for developing synthetic macrocycles. These macrocycles aim to expand the druggable genome by combining the properties of peptides and small molecules.
Key investors expressed confidence in UNP's potential to impact drug development and patient care. A biotech company based in California called UNP receives funding from various projects concentrating on medicinal chemistry and machine learning.
For more details, please refer to the full article.
Key investors expressed confidence in UNP's potential to impact drug development and patient care. A biotech company based in California called UNP receives funding from various projects concentrating on medicinal chemistry and machine learning.
For more details, please refer to the full article.